(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of 12.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Mimedx Group's revenue in 2025 is $348,879,000.On average, 1 Wall Street analysts forecast MDXG's revenue for 2025 to be $55,262,271,000, with the lowest MDXG revenue forecast at $55,262,271,000, and the highest MDXG revenue forecast at $55,262,271,000.
In 2026, MDXG is forecast to generate $63,367,404,080 in revenue, with the lowest revenue forecast at $63,367,404,080 and the highest revenue forecast at $63,367,404,080.